Gepotidacin (GSK2140944): A Novel Bacterial Type II Topoisomerase Inhibitor for Antibacterial Research

Executive Summary: Gepotidacin (GSK2140944) is a triazacyclopentadiene derivative that inhibits bacterial type II topoisomerase, disrupting bacterial DNA replication and transcription (Watkins et al., 2023). It demonstrates bactericidal activity against Gram-negative pathogens, including Escherichia coli and Neisseria gonorrhoeae, with efficacy in Phase II clinical trials (doi). Resistance requires dual mutations in both target enzymes, suggesting a high barrier to resistance development (doi). Gepotidacin is provided by APExBIO as a solid (MW 448.52, C24H28N6O3) for research use only (product page). Optimal storage is at -20°C, and solutions should be used promptly for maximal activity.

Biological Rationale

Bacterial infections remain a leading cause of morbidity and mortality worldwide. The rise of antimicrobial resistance (AMR) in Gram-negative organisms, particularly in urinary tract infections (UTIs) and urogenital gonorrhoea, presents a major clinical challenge (Watkins et al., 2023). Traditional antibiotics, such as quinolones and beta-lactams, have become less effective due to multidrug-resistant (MDR) strains (doi). Gepotidacin offers a distinct mechanism by selectively targeting bacterial type II topoisomerases, critical enzymes for DNA supercoiling and replication. This unique action disrupts bacterial proliferation, addressing the urgent need for novel antibacterial agents (doi).

Mechanism of Action of Gepotidacin (GSK2140944)

Gepotidacin is structurally classified as a triazacyclopentadiene antibacterial agent (APExBIO). It inhibits bacterial type II topoisomerases, specifically DNA gyrase and topoisomerase IV, essential for managing DNA supercoiling during replication and transcription (doi). Gepotidacin binds at a novel site distinct from fluoroquinolones, preventing DNA religation and causing lethal double-strand breaks (doi). This mechanism requires bacteria to acquire simultaneous mutations in both enzyme subunits for resistance, a rare event that enhances its utility in antibiotic resistance research (doi).

Evidence & Benchmarks

• Gepotidacin displays potent in vitro activity against MDR E. coli and Neisseria gonorrhoeae (Watkins et al., 2023, doi).
• Phase II clinical trials demonstrated efficacy in treating uncomplicated UTIs and urogenital gonorrhoea (Watkins et al., 2023, doi).
• Bactericidal concentrations (MIC90) for UPEC strains typically range from 0.5–4 μg/mL under standard CLSI conditions (doi).
• Resistance development requires mutations in both topoisomerase IV and DNA gyrase, conferring a high genetic barrier (Watkins et al., 2023, doi).
• Unique binding mode confirmed by X-ray crystallography and biochemical assays (doi).

This article builds on previous mechanistic reviews by adding peer-reviewed clinical trial results and specific stability recommendations for laboratory workflows.

For a practical focus on assay deployment, see this protocol-oriented article, which complements the current overview by providing validated assays and troubleshooting guidance.

Applications, Limits & Misconceptions

Gepotidacin is intended for antibacterial research, particularly in studies of DNA replication inhibition, antibiotic resistance, and novel antibiotic development. It is a valuable tool for screening MDR bacterial strains, elucidating topoisomerase function, and benchmarking new compounds.

Common Pitfalls or Misconceptions

• Not for Human or Veterinary Use: Gepotidacin (GSK2140944) from APExBIO is for research use only and is not approved for clinical or diagnostic applications (product page).
• Storage Stability: Long-term storage of prepared solutions is not advised; activity may decline rapidly at room temperature or after repeated freeze-thaw cycles (product page).
• Mechanism Specificity: Gepotidacin is ineffective against organisms lacking bacterial type II topoisomerases, such as fungi or viruses.
• Resistance Risk: While resistance requires dual mutations, improper use at sublethal concentrations may still select resistant variants over time (doi).
• Solvent Compatibility: Gepotidacin is supplied as a 10 mM solution in DMSO; alternative solvents may affect solubility and activity.

Workflow Integration & Parameters

For laboratory research, Gepotidacin (SKU BA1220) is typically reconstituted to 10 mM in DMSO and aliquoted for single-use applications (Gepotidacin product page). Store the solid compound at -20°C, protected with blue ice during shipping. Use freshly prepared aliquots for cell-based or biochemical assays to ensure maximal potency. Standardized MIC testing should follow CLSI guidelines, using Mueller–Hinton broth at 35°C and pH 7.2–7.4. The compound is compatible with most viability, proliferation, and cytotoxicity assay platforms (see detailed workflow strategies), but users should avoid repeated freeze-thaw cycles.

Conclusion & Outlook

Gepotidacin (GSK2140944) represents a significant advance in antibacterial research, providing a new option for targeting bacterial type II topoisomerases and overcoming current resistance mechanisms (Watkins et al., 2023). Its robust genetic barrier to resistance, unique mechanism, and proven efficacy in clinical studies position it as a core tool for antibiotic resistance and novel drug development research. For additional mechanistic insight and translational opportunities, see related reviews (mechanistic innovation; future directions), which this article updates with the latest data and workflow recommendations.

This dossier was curated from peer-reviewed literature and the APExBIO product specification for Gepotidacin (GSK2140944) (SKU BA1220).